H-SLFRAVITK^-OH

Ref. 3D-PP42137

Informations sur le produit

• Nom: H-SLFRAVITK^-OH

Description

Peptide H-SLFRAVITK^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SLFRAVITK^-OH include the following: Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B* 5701 tumors V Corbiere , H Nicolay , V Russo, V Stroobant - Tissue , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.0001-2815.2004.00203.x Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. SC Threlkeld, PA Wentworth, SA Kalams - (Baltimore, Md.: 1950 , 1997 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/159/4/1648/42488 A NOVel ELISPOT assay to quantify HLA-specific B cells in HLA-immunized individuals S Heidt , DL Roelen, YJH de Vaal, MGD Kester - American journal of , 2012 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1600613522274760 A reversible functional defect of CD8+ T lymphocytes involving loss of tetramer labeling N Demotte, D Colau, S Ottaviani - European journal of , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200206)32:6%3C1688::AID-IMMU1688%3E3.0.CO;2-9 Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation M Widenmeyer, Y Shebzukhov - Journal of Cancer, 2011 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.25601 Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies KA Chianese-Bullock, ST Lewis, NE Sherman - Vaccine, 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X09000553 MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA KA Chianese-Bullock, J Pressley, C Garbee - The Journal of , 2005 - journals.aai.orghttps://journals.aai.org/jimmunol/article/174/5/3080/36807 First clinical experience: osteosarcoma patient vaccinated with monocyte-derived dendritic cells, pulsed with tumor specific MAGE-peptides JFM Jacobs, GJ Adema, IJM de Vries - PDF hosted at the , 2009 - core.ac.ukhttps://core.ac.uk/download/pdf/16158885.pdf#page=96 Peptide vaccination in montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T E Clancy-Thompson, LK King, LD Nunnley - Cancer immunology , 2013 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/1/5/332/466869 Stability of Multi-Peptide Vaccines in Conditions Enabling Accessibility in Limited Resource Settings E Ashkani, B McKenna, J Bryant, D Silva, N Sherman - 2024 - researchsquare.comhttps://www.researchsquare.com/article/rs-4345166/latest Effect of GM-CSF on circulating CD8+ and CD4+ T cell responses to a multipeptide melanoma vaccine: Outcome of a multicenter randomized trial CL Slingluff Jr , GR Petroni , WC Olson - cancer research: an , 2009 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778314/ Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a CL Slingluff Jr , GR Petroni , WC Olson, ME Smolkin - Clinical Cancer , 2009 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/15/22/7036/74944 Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma C Capasso, M Hirvinen, M Garofalo , D Romaniuk - , 2016 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2015.1105429

• Marque: Biosynth